Search

everythinglearnresearchcommunity

for

Search:↓

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Finasteride may cause breast enlargement, low testosterone a risk factor.

Certain drugs that block specific enzymes can help treat prostate diseases.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Physical activity, height, and smoking affect prostate cancer risk.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Hair loss gene linked to prostate issues.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.